SG10201700169PA - Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides - Google Patents
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptidesInfo
- Publication number
- SG10201700169PA SG10201700169PA SG10201700169PA SG10201700169PA SG10201700169PA SG 10201700169P A SG10201700169P A SG 10201700169PA SG 10201700169P A SG10201700169P A SG 10201700169PA SG 10201700169P A SG10201700169P A SG 10201700169PA SG 10201700169P A SG10201700169P A SG 10201700169PA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptides
- expression vector
- vector element
- cell generation
- generation methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11195361 | 2011-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201700169PA true SG10201700169PA (en) | 2017-02-27 |
Family
ID=47504950
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201700169PA SG10201700169PA (en) | 2011-12-22 | 2012-12-19 | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
| SG10201900915WA SG10201900915WA (en) | 2011-12-22 | 2012-12-19 | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
| SG11201403443WA SG11201403443WA (en) | 2011-12-22 | 2012-12-19 | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201900915WA SG10201900915WA (en) | 2011-12-22 | 2012-12-19 | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
| SG11201403443WA SG11201403443WA (en) | 2011-12-22 | 2012-12-19 | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20160208284A1 (en) |
| EP (2) | EP2794651B1 (en) |
| JP (4) | JP6096802B2 (en) |
| KR (4) | KR102229491B1 (en) |
| CN (4) | CN113881702A (en) |
| BR (1) | BR112014014239B1 (en) |
| CA (2) | CA3149402A1 (en) |
| ES (1) | ES2930215T3 (en) |
| HK (1) | HK1200848A1 (en) |
| HR (1) | HRP20221383T1 (en) |
| MX (2) | MX370481B (en) |
| PL (1) | PL2794651T3 (en) |
| RU (2) | RU2756910C2 (en) |
| SG (3) | SG10201700169PA (en) |
| WO (1) | WO2013092743A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11046975B2 (en) | 2013-10-07 | 2021-06-29 | Prestige Biopharma Pte. Ltd. | Bicistronic expression vector for antibody expression and method for producing antibody using same |
| CN105255867A (en) * | 2015-10-19 | 2016-01-20 | 北京益生合生物科技有限公司 | Gene sequence capable of preventing gradual inactivation of promoter in subculture and applications of gene sequence |
| ES2823173T3 (en) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Hybrid promoter and uses of it |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| EP3528852A4 (en) | 2016-10-20 | 2020-06-03 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of fabry disease |
| CN110636859B (en) * | 2017-05-19 | 2024-05-03 | 科学与工业研究委员会 | Methods for producing refolded recombinant humanized ranibizumab |
| JP7081139B2 (en) * | 2017-12-20 | 2022-06-07 | 東ソー株式会社 | New promoter and expression vector containing it |
| AU2019342866A1 (en) * | 2018-09-20 | 2021-05-20 | Sanofi | Intron-based universal cloning methods and compositions |
| KR102559149B1 (en) * | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | Multispecific antibody screening method using recombinase-mediated cassette exchange |
| CN117043194A (en) | 2021-01-29 | 2023-11-10 | 默沙东有限责任公司 | Compositions of programmed death receptor 1 (PD-1) antibodies and methods of obtaining the same |
| KR102640929B1 (en) | 2023-06-02 | 2024-02-27 | (주) 멥스젠 | Microphysiological system forming device |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| DE3883899T3 (en) | 1987-03-18 | 1999-04-22 | Sb2 Inc | CHANGED ANTIBODIES. |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| JP3051411B2 (en) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | Novel DNA and expression plasmid containing it |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE164395T1 (en) | 1990-12-03 | 1998-04-15 | Genentech Inc | METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69334255D1 (en) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker for cancer and biosynthetic binding protein for it |
| RU2201449C2 (en) * | 1994-10-14 | 2003-03-27 | Сембайозис Дженетикс Инк. | Fused polypeptide able to purposeful transfer to oily body, chimeric dna-construction, expressing cassette |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| EP0994903B1 (en) | 1997-06-24 | 2005-05-25 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| BR9813365A (en) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Method for Production and Humanization of a Mouse Monoclonal Antibody |
| DK2180007T4 (en) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity |
| PT1176195E (en) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Method for controlling the activity of immunologically functional molecule |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| KR100797667B1 (en) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | Method for regulating transcription of foreign genes |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| DK2857516T3 (en) | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
| KR100408844B1 (en) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | Expression vector using for animal cell |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| KR100857943B1 (en) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | Transgenic Transchromosomal Rodents for Making Human Antibodies |
| MXPA04001072A (en) | 2001-08-03 | 2005-02-17 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity. |
| US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| KR100988949B1 (en) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | Glycoprotein compositions |
| EA007905B1 (en) * | 2001-11-16 | 2007-02-27 | Байоджен Айдек Инк. | Polycistronic expression of antibodies |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | Drug containing antibody composition |
| PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| DE60336548D1 (en) | 2002-04-09 | 2011-05-12 | Kyowa Hakko Kirin Co Ltd | CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP FUCOSET TRANSPORT |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | Process for producing antibody composition |
| JP4753578B2 (en) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | Synthetic antibody phage library |
| SI2289936T1 (en) | 2002-12-16 | 2017-10-30 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CN100383244C (en) * | 2003-01-07 | 2008-04-23 | 西福根有限公司 | Method for manufacturing recombinant polyclonal proteins |
| AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2005035586A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
| LT2380911T (en) | 2003-11-05 | 2018-07-10 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
| CN1961003B (en) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | Humanized anti-TGF-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
| CN101001953B (en) * | 2004-06-17 | 2013-03-13 | 惠氏公司 | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
| CN101292036B (en) * | 2005-10-21 | 2016-04-13 | 弗·哈夫曼-拉罗切有限公司 | For the method for recombinant expressed polypeptide |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| JP2009536527A (en) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | Binding polypeptide with optimized scaffold |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| WO2008077545A1 (en) * | 2006-12-22 | 2008-07-03 | F. Hoffmann-La Roche Ag | Selection method |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| NZ580378A (en) * | 2007-03-30 | 2012-11-30 | Abbott Lab | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| CN100592373C (en) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | Liquid crystal panel drive device and its drive method |
| KR101183764B1 (en) * | 2007-06-29 | 2012-09-17 | 에프. 호프만-라 로슈 아게 | Promoter |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| JP5788796B2 (en) * | 2008-08-28 | 2015-10-07 | ノバルティス アーゲー | Cell surface presentation of polypeptide isoforms by stop codon readthrough |
| GB0903207D0 (en) * | 2009-02-25 | 2009-04-08 | Ucb Pharma Sa | Method for expressing multimeric proteins |
| JP5501439B2 (en) | 2009-04-02 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | Multispecific antibody comprising a full-length antibody and a single chain Fab fragment |
| JP5616428B2 (en) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | Trivalent bispecific antibody |
| EP2435473B1 (en) | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
-
2012
- 2012-12-19 EP EP12810245.6A patent/EP2794651B1/en active Active
- 2012-12-19 ES ES12810245T patent/ES2930215T3/en active Active
- 2012-12-19 RU RU2017140661A patent/RU2756910C2/en active
- 2012-12-19 BR BR112014014239-4A patent/BR112014014239B1/en active IP Right Grant
- 2012-12-19 US US14/367,680 patent/US20160208284A1/en not_active Abandoned
- 2012-12-19 CN CN202111170578.8A patent/CN113881702A/en active Pending
- 2012-12-19 CN CN201710324350.7A patent/CN107119073A/en active Pending
- 2012-12-19 SG SG10201700169PA patent/SG10201700169PA/en unknown
- 2012-12-19 SG SG10201900915WA patent/SG10201900915WA/en unknown
- 2012-12-19 CN CN201280062793.9A patent/CN104011075B/en active Active
- 2012-12-19 CA CA3149402A patent/CA3149402A1/en active Pending
- 2012-12-19 HR HRP20221383TT patent/HRP20221383T1/en unknown
- 2012-12-19 PL PL12810245.6T patent/PL2794651T3/en unknown
- 2012-12-19 KR KR1020207007391A patent/KR102229491B1/en active IP Right Grant
- 2012-12-19 JP JP2014547983A patent/JP6096802B2/en active Active
- 2012-12-19 WO PCT/EP2012/076203 patent/WO2013092743A2/en active Application Filing
- 2012-12-19 RU RU2014129727A patent/RU2639519C2/en active
- 2012-12-19 CA CA2854249A patent/CA2854249C/en active Active
- 2012-12-19 CN CN202111171021.6A patent/CN113896787A/en active Pending
- 2012-12-19 KR KR1020197034166A patent/KR102166824B1/en active IP Right Grant
- 2012-12-19 MX MX2017012736A patent/MX370481B/en unknown
- 2012-12-19 EP EP18157484.9A patent/EP3354660A1/en active Pending
- 2012-12-19 KR KR1020217007341A patent/KR102285184B1/en active IP Right Grant
- 2012-12-19 MX MX2014007359A patent/MX355624B/en active IP Right Grant
- 2012-12-19 SG SG11201403443WA patent/SG11201403443WA/en unknown
- 2012-12-19 KR KR1020147016825A patent/KR102048556B1/en active IP Right Grant
-
2015
- 2015-02-04 HK HK15101213.2A patent/HK1200848A1/en unknown
-
2017
- 2017-02-16 JP JP2017026502A patent/JP6417436B2/en active Active
-
2018
- 2018-10-05 JP JP2018189605A patent/JP2019030311A/en active Pending
-
2019
- 2019-12-09 JP JP2019221805A patent/JP7096806B2/en active Active
-
2020
- 2020-07-06 US US16/921,194 patent/US20210024952A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271870B (en) | Factor viii chimeric and hybrid polypeptides, and methods of use thereof | |
| HK1200848A1 (en) | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides | |
| IL260045B (en) | Polypeptide constructs and uses thereof | |
| HRP20190484T1 (en) | Cell culture compositions and methods for polypeptide production | |
| HK1209651A1 (en) | Cells for producing recombinant iduronate-2-sulfatase -2- | |
| IL222454B (en) | Process for the production of recombinant polypeptides | |
| PL2836511T3 (en) | Polypeptide useful in adoptive cell therapy | |
| HK1250743A1 (en) | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides | |
| IL222453B (en) | Process for the production of recombinant polypeptides | |
| EP2935581A4 (en) | Expression vectors for recombinant protein production in mammalian cells | |
| SG11201402139UA (en) | High mast2-affinity polypeptides and uses thereof | |
| HK1210193A1 (en) | Method for the production of polypeptides in the periplasm of prokaryotic cells |